To add, I would say acquisitions are probably also driven a lot by how compelling the asset/s are, and not just by time. Plenty of biotechs who have to do phase 3 trials alone, and then there are some biotechs who are snapped up after Phase I. CHM's assets are clearly interesting enough to bring established professionals into a tiny Australian biotech.
I feel lucky to be in this early. IMO
To add, I would say acquisitions are probably also driven a lot...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
